How the Oncotype IQ Platform Delivers Healthcare Savings

The problem of waste in cancer therapeutics

More than $100 billion is spent each year on cancer drugs worldwide to improve the lives of men and women diagnosed with cancer.1 However, with an average efficacy rate of only 25%,2 most patients do not experience significant clinical benefit—resulting in more than $75 billion in annual spending on ineffective treatments.

Watch: How Exact Sciences (formerly Genomic Health) is leading the way toward smarter cancer care with precision medicine

The Oncotype IQ Platform and our proven cost savings

Precision medicine offers the opportunity to solve this problem. Exact Sciences delivers on the promise of precision medicine, having tested over 1 million patients in over 90 countries, and saving the healthcare system an estimated $5 billion in the United States alone.3 For over a decade we’ve provided patients with personalized biological information that helps them get the right treatment at the right time, and to avoid unnecessary treatments and their side effects. Our robust Oncotype IQ Genomic Intelligence Platform includes a suite of tissue-based tests as well as liquid biopsy tests that answer specific and critical questions throughout the cancer journey.

Oncotype DX for breast cancer patients

The Oncotype DX test for breast cancer is the best example of precision medicine for cancer patients. It addresses the problem that only about 4 in 100 women who are diagnosed with early stage breast cancer benefit from chemotherapy.4


Oncotype DX is the only genomic test proven to identify patients who will likely benefit from chemotherapy—as well as those who won’t, so they can confidently and safely avoid unnecessary side effects. With an impressive body of clinical evidence, Oncotype DX is recognized as the standard of care in early breast cancer.

The healthcare savings made possible by Oncotype DX have been documented in pharmacoeconomic studies.

  • The Oncotype DX Breast Recurrence Score results can save up to $49 million in short term health care costs for women with early-stage breast cancer5
  • Ductal carcinoma in situ (DCIS): Investigators predicted an average savings of $1,000 per patient.6

Oncotype DX for prostate cancer patients

For the 135,000 men who are diagnosed with clinically low-risk prostate cancer each year, the Oncotype Genomic Prostate Score estimates cancer risk and can guide decisions about need for immediate treatment.


Alternatively, for men with a favorable prognosis, the test can help them confidently choose active surveillance, and avoid the serious side effects of surgery or radiation. Oncotype DX is estimated to yield a net savings of over $2,000 per patient by decreasing unnecessary invasive treatment,7 and poised to save the US healthcare system well over $100 million each year of direct costs.8



Delivering on the promise of precision medicine

Looking ahead, we will continue to expand our Oncotype IQ Genomic Intelligence Platform through product development and strategic partnerships—all with mission of delivering precision medicine to make cancer care smarter.


1. Aitken. IMS Institute for Healthcare Informatics. 2016.
2. Adams, Brantner. Health Affairs. 2006.
3. Data on file, Genomic Health Inc. 2016.
4. Paik et al. J Clin Oncol. 2006.
5. Mariotto et al. JNCI. 2019.
6. Alvarado et al. Cancer Res. 2012.
7. Albala et al. Rev Urol.
8. Data on file, Genomic Health Inc. 2016.

a. DOI: 10.1002/cncr.22506
b. DOI: 10.1158/0008-5472
c. DOI: 10.3909/riu0725

Various statements made on this page that are not historical, including those about our future financial and operating results, business strategy, goals and priorities, plans and prospects, growth opportunities and the potential size of addressable markets, the value of our tests, correlation of test growth to future revenue, ability to secure market access in global markets, our product pipeline and potential new products or applications, timing of future product releases, collaborations, and the occurrence, timing and results of clinical studies, constitute forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties include, but are not limited to: our ability to increase usage of our tests; risks associated with possible regulation of our tests by the FDA or similar regulatory agencies outside the United States; risks and uncertainties associated with development and commercialization efforts; the risk that we may not obtain or maintain sufficient levels of reimbursement for our existing tests and future tests we may develop; the risks associated with sales and operations globally; our history of operating losses; the occurrence, timing, results and applicability of clinical study results to actual outcomes; and the other risks set forth in our filings with the Securities and Exchange Commission, including the risks set forth in our Quarterly Report on Form 10-Q for the most recent quarter ended. These forward-looking statements speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Making cancer care smarter.™

We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.